Platelet donor database: a study on the specialist donor database for the patients with alloimmune thrombocytopenia in the Chinese population and the assessment of completeness

To the Editor: Due to the immunogenicity of the platelet antigens, especially blood group antigen (such as ABO antigens), human leukocyte antigen (HLA), human platelet antigen (HPA), and CD36 (platelet glycoproteins IV), which can produce corresponding alloantibodies through immune factors such as blood transfusion, pregnancy, and drugs, the immune reaction of the platelet antigens and antibodies in patients will lead to various types of alloimmune thrombocytopenia, including the immune platelet transfusion refractoriness, post-transfusion purpura, and fetal/neonatal alloimmune thrombocytopenia. [2–4] Based on the analysis of the characteristics of HLA-A and -B gene polymorphisms and the cross-reactive groups (CREGs) of the population in the Nanning area (7001 samples detected), the HPA-1-17w gene polymorphisms of the population in the Nanning area (4243 samples detected), and the incidence rate of CD36 deficiency in individuals and ABO blood group distribution characteristics of the apheresis platelet donors in the Nanning area (5081 samples detected), a PDD consisting of the database of donors with known HLA, HPA, and CD36 deficiency was constructed. Funding This study was supported by grants from the Major Program of Nanning Scientific Research and Technological Development Plan Project, China (grant no. 20173117), the Guangxi Scientific Research and Technological Development Plan Project, China (grant no. 08160-06), and the Guangxi Natural Science Foundation, China (grant nos. 2016GXNSFAA380143 and 2013 GXNSFBA019206).